Gainers
Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of Radiation-Related Disorders."
Reflects continued progress in the business combination process; transaction remains on schedule to be completed during the second half of 2022
Includes Dragonfly's latest quarterly results for the first